Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly

Journal of Diabetes

Volumn 7, Issue 1, 2015, Pages 60-67

  Paul, Sanjoy K ^a   Maggs, David ^a   Klein, Kerenaftali ^b   Best, Jennie H ^a,c  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b Bristol Myer Squib   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Glucagon like peptide 1 receptor agonist; Hypoglycemia risk factors; Insulin glargine; Tight glycemic control and body weight interaction

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; GLARGINE; GLUCOSE BLOOD LEVEL; LONG ACTING INSULIN; PEPTIDE; VENOM;

ANALYSIS; BODY MASS; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LONGITUDINAL STUDY; MALE; MIDDLE AGED; RISK FACTOR;

BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PEPTIDES; RISK FACTORS; VENOMS;

EID: 84920046998     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12208     Document Type: Article

References (30)

1. Seaquist ER, Anderson J, Childs B etal. Hypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013; 36: 1384-1395.
2. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration. Diabetologia. 2007; 50: 1140-1147.
3. Zoungas S, Patel A, Chalmers J etal. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010; 363: 1410-1418.
4. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003; 26: 1902-1912.
5. Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycaemia in insulin-treated type 2 diabetes: Frequency, symptoms and impaired awareness. Diabet Med. 2003; 20: 1016-1021.
6. Khunti K, Fisher H, Paul S, Mohammad I, Davies MJ, Siriwardena AN. Characteristics and costs of individuals experiencing severe hypoglycaemia requiring emergency ambulance assistance in the community. Diabetologia. 2012; 55: S255-256.
7. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care. 2010; 33: 1389-1394.
8. Arakawa M, Mita T, Azuma K etal. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 2010; 59: 1030-1037.
9. Brodovicz KG, Mehta V, Zhang Q etal. Association between hypoglycemia and inpatient mortality and length of hospital stay in hospitalized, insulin-treated patients. Curr Med Res Opin. 2013; 29: 101-107.
10. Khunti K, Fisher H, Paul S, Iqbal M, Davies MJ, Siriwardena AN. Severe hypoglycaemia requiring emergency medical assistance by ambulance services in the East Midlands: A retrospective study. Prim Care Diabetes. 2013; 7: 159-165.
11. Karl DM, Gill J, Zhou R, Riddle MC. Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus. Diabetes Obes Metab. 2013; 15: 622-628.
12. Cryer PE, Irene E, Karl MM. Insulin therapy and hypoglycemia in type 2 diabetes mellitus. Insulin. 2007; 2: 127-133.
13. Donnelly LA, Morris AD, Frier BM etal. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: A population-based study. Diabet Med. 2005; 22: 749-755.
14. Holman RR, Thorne KI, Farmer AJ etal. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007; 357: 1716-1730.
15. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: A review of their efficacy and tolerability. Diabetes Care. 2011; 34: S279-284.
16. Diamant M, Van Gaal L, Stranks S etal. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial. Lancet. 2010; 375: 2234-2243.
17. Buse JB, Drucker DJ, Taylor KL etal. DURATION-1 exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010; 33: 1255-1261.
18. Blevins T, Pullman J, Malloy J etal. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011; 96: 1301-1310.
19. Bergenstal RM, Wysham C, MacConell L etal. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial. Lancet. 2010; 376: 431-439.
20. Diamant M, Van Gaal L, Guerci B etal. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol. 2014; 2: 464-473.
21. Wang Y, Li L, Yang M, Liu H, Boden G, Yang G. Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: A meta-analysis of clinical trials. Diabetes Obes Metab. 2011; 13: 972-981.
22. Karl DM, Gill J, Zhou R, Riddle MC. Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus. Diabetes Obes Metab. 2013; 15: 622-628.
23. Sämann A, Lehmann T, Heller T etal. A retrospective study on the incidence and risk factors of severe hypoglycemia in primary care. Fam Pract. 2013; 30: 290-293.
24. Seufert J, Brath H, Pscherer S, Borck A, Bramlage P, Siegmund T. Composite efficacy parameters and predictors of hypoglycaemia in basal-plus insulin therapy: A combined analysis of 713 type 2 diabetic patients. Diabetes Obes Metab. 2013; 16: 248-254.
25. Bruderer SG, Bodmer M, Jick SS, Bader G, Schlienger RG, Meier CR. Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK: A nested case-control analysis. Diabetes Obes Metab. 2014; 16: 801-811.
26. Wysham C, Bergenstal R, Malloy J etal. DURATION-2: Efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med. 2011; 28: 705-714.
27. Diamant M, Van Gaal L, Stranks S etal. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care. 2012; 35: 683-689.
28. Drucker DJ, Buse JB, Taylor K etal. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. Lancet. 2008; 372: 1240-1250.
29. Chan JYC, Leyk M, Frier BM, Tan MH. Relationship between HbA1c and hypoglycaemia in patients with type 2 diabetes treated with different insulin regimens in combination with metformin. Diabetes Metab Res Rev. 2009; 25: 224-231.
30. Amylin Pharmaceuticals Inc. Product Information Bydureon (Exenatide Extended-Release for Injectable Suspension). Amylin Pharmaceuticals Inc., San Diego, CA, 2012.